These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 6921959)

  • 21. In vitro comparison of cefoxitin, cefamandole, cephalexin, and cephalothin.
    Eickhoff TC; Ehret JM
    Antimicrob Agents Chemother; 1976 Jun; 9(6):994-9. PubMed ID: 938029
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cefamandole and cefoxitin.
    Med Lett Drugs Ther; 1979 Feb; 21(3):13-5. PubMed ID: 310945
    [No Abstract]   [Full Text] [Related]  

  • 23. Sensitivity of gentamicin-resistant Enterobacteriaceae to cefamandole and cefoxitin.
    Rosenthal SL; Freundlich LF; Quraishi MA
    Chemotherapy; 1979; 25(3):157-61. PubMed ID: 456076
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vivo inoculum effect and resistance selection with cefamandole and cefoxitin against Enterobacter cloacae in mice.
    Miller AK; Celozzi E; Pelak BA; Birnbaum J; Stapley EO
    J Antimicrob Chemother; 1980 Nov; 6(6):804-6. PubMed ID: 7002900
    [No Abstract]   [Full Text] [Related]  

  • 25. Activity of cefamandole, cefoxitin, ampicillin and gentamicin against 419 bacteria isolated from blood of patients with sepsis.
    Mirrett S; Reller LB
    Chemotherapy; 1980; 26(6):436-45. PubMed ID: 7408556
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro antibacterial activity of a new 1-oxa cephalosporin compound.
    Downs JT; Andriole VT
    Yale J Biol Med; 1980; 53(2):149-59. PubMed ID: 6446810
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ["In vitro" activity of cefamandole, cefalotin, cefoxitin and cefuroxim against enterobacteria and Staphylococcus aureus isolated in hospital (author's transl)].
    Thabaut A; Durosoir JL; Saliou P
    Pathol Biol (Paris); 1979 Dec; 27(10):649-54. PubMed ID: 395496
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Progress in antibacterial chemotherapy].
    Naumann P; Rosin H
    Verh Dtsch Ges Inn Med; 1978; (84):427-38. PubMed ID: 369199
    [No Abstract]   [Full Text] [Related]  

  • 29. In vitro activity of cefoxitin and parenterally administered cephalosporins against anaerobic bacteria.
    Sutter VL; Kirby B; Finegold SM
    Rev Infect Dis; 1979; 1(1):218-23. PubMed ID: 318226
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evidence for nonspecific induction of beta-lactamase in overproducing variants of Enterobacter cloacae and Citrobacter freundii.
    Cullmann W; Dick W
    Eur J Clin Microbiol; 1985 Feb; 4(1):34-40. PubMed ID: 3872794
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Type I beta-lactamases of Enterobacter cloacae and resistance to beta-lactam antibiotics.
    Tejedor-Junco MT; González-Martín M; Lupiola P; González-Lama Z
    Folia Microbiol (Praha); 1998; 43(6):683-6. PubMed ID: 10069013
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lack of in vitro activity of cefoxitin, cefamandole, cefuroxime, and piperacillin against Chlamydia trachomatis.
    Bowie WR
    Antimicrob Agents Chemother; 1982 Feb; 21(2):339-40. PubMed ID: 6462108
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative in vivo efficiency of cefamandole and cefoxitin against Bacteroides fragilis.
    Bergeron MG; Gauvreau L; Nguyen BM
    Scand J Infect Dis Suppl; 1980; suppl 25():60-5. PubMed ID: 6937954
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of beta-lactamase stability, penetration, and target affinity on the activity of cefazolin, cefamandole, cefoxitin, and cefuroxime.
    Harper PB
    Clin Ther; 1984; 6(3):310-24. PubMed ID: 6609771
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of a cefoxitin-inducible beta-lactamase in a case of breakthrough bacteremia.
    Beckwith DG; Jahre JA
    J Clin Microbiol; 1980 Oct; 12(4):517-20. PubMed ID: 6968320
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effects on beta-lactam susceptibility of phenotypic induction and genotypic derepression of beta-lactamase synthesis.
    Shannon K; Phillips I
    J Antimicrob Chemother; 1986 Dec; 18 Suppl E():15-22. PubMed ID: 3102451
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Resistance to cefamandole: a collaborative study of emerging clinical problems.
    Sanders CC; Moellering RC; Martin RR; Perkins RL; Strike DG; Gootz TD; Sanders WE
    J Infect Dis; 1982 Jan; 145(1):118-25. PubMed ID: 6274965
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A randomized study of carbenicillin plus cefamandole or tobramycin in the treatment of febrile episodes in cancer patients.
    Bodey GP; Ketchel SJ; Rodriguez V
    Am J Med; 1979 Oct; 67(4):608-16. PubMed ID: 495630
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison between agar and broth minimum inhibitory concentrations of cefamandole, Cefoxitin, and cefuroxime.
    Rylander M; Brorson JE; Johnsson J; Norrby R
    Antimicrob Agents Chemother; 1979 Apr; 15(4):572-9. PubMed ID: 464588
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost containment of the second-generation cephalosporins by prospective monitoring at a community teaching hospital.
    Williams RR; Gross PA; Levine JF
    Arch Intern Med; 1985 Nov; 145(11):1978-81. PubMed ID: 4062447
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.